IV lidocaine versus IV dexmedetomidine for pain control during sleeve gastrectomy

Intravenous Lidocaine Infusion Versus Intravenous Dexmedetomidine Infusion During Laparoscopic Sleeve Gastrectomy : the Effect on Recovery Outcomes Variables

It tests whether an IV infusion of lidocaine or dexmedetomidine given during laparoscopic sleeve gastrectomy helps reduce early postoperative pain and the need for opioid pain medicines in adults aged 20–50 with BMI 35–50.

Quick facts

• Phase: NA
• Study type: Interventional
• Enrollment: 40 (estimated)
• Ages: 20 Years to 50 Years
• Sex: All
• Sponsor: Alexandria University (other)
• Locations: 1 site (Alexandria)
• Trial ID: NCT07327905 on ClinicalTrials.gov

What this trial studies

This interventional comparison gives participants one of two intravenous infusions—lidocaine or dexmedetomidine—around the time of laparoscopic sleeve gastrectomy. Adults aged 20–50 with BMI 35–50 and ASA physical status II–III are enrolled and monitored for pain scores, opioid consumption, sedation, and adverse events in the early postoperative period. The protocol tracks safety issues such as cardiac conduction and hemodynamic stability as well as analgesic and anti-inflammatory effects. Patients with cardiac conduction disorders, cardiomyopathy, chronic opioid use, allergy to study drugs, or pregnancy/breastfeeding are excluded.

Who should consider this trial

Good fit: Adults aged 20–50 years with BMI 35–50 kg/m2, ASA class II–III, scheduled for laparoscopic sleeve gastrectomy and without contraindications to lidocaine or dexmedetomidine would be ideal candidates.

Not a fit: Patients with cardiac conduction disorders, cardiomyopathy, chronic opioid dependence, allergy to the study drugs, or who are pregnant or breastfeeding are unlikely to benefit or be eligible.

Why it matters

Potential benefit: If successful, the approach could give better early pain relief with less opioid use and fewer opioid-related side effects after sleeve gastrectomy.

How similar studies have performed: Both intravenous lidocaine and dexmedetomidine have shown benefit in prior surgical studies for reducing postoperative pain and opioid use, but direct head-to-head data specifically in sleeve gastrectomy are limited.

Eligibility criteria

Inclusion Criteria:

* Age: 20-50 years, both sexes.
* American Standards Association (ASA) physical status class II to III.
* Body mass index (BMI) 35-50 kg m-².

Exclusion Criteria:

* Cardiac conduction disorders.
* Cardiomyopathy.
* Chronic opioid use.
* Allergy to the studied medications.
* Pregnancy and breastfeeding.

Where this trial is running

Alexandria

• Alexandria University — Alexandria, Egypt (RECRUITING)

Study contacts

• Principal investigator: sarah m elgamal, MD — Alexandria University
• Study coordinator: sarah m elgamal, MD

Conditions: Bariatric Surgery, Lidocaine, Dexmedetomidine, lidocaine, dexmedetomidine, bariatric